Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
DOI:
https://doi.org/10.26641/2307-0404.2015.3.53687Keywords:
chronic myeloid leukemia, kinase domain mutations of BCR-ABL gene, chromosome aberrations, imatinib, nilotinibAbstract
Aim of this study was to analyze molecular genetic and cytogenetic reasons for disease resistance to tyrosine kinase inhibitors (TKI) imatinib (IM) and nilotinib (NI) in patients with chronic myeloid leukemia (CML). Material and methods. A group of 32 CML patients with primary or acquired resistance to TKI treatment was investigated. Cytogenetic response was determined by conventional karyotyping with differential banding. Presence of BCR-ABL kinase domain mutations was investigated by direct sequencing. Results and discussion. The frequency of mutations was 37% (12 patients) with prevailing occurrence of mutations with low sensitivity to nilotinib – E255K/V; Т315I; F359V; Y253H. In 47% of the cases (15 patients) additional chromosome aberrations (ACA) were revealed which could also be the reason for TKI resistance in patients without BCR/ABL mutations. Patients with detected mutations of BCR/ABL gene were either switched to nilotinib or treated with increased dose of IM. Cytogenetic response was achieved in only 2 patients with mutations and in 12 patients without them. Frequency of blast crisis development did not differ significantly in both groups. Conclusions. Among the investigated patients with CML resistant to IM BCR/ABL gene mutations were detected in more than third of the cases whereas ACA were found in almost half of the group. Taking into account revealed prevalence of mutations not sensitive to the 2nd generation TKI nilotinib, investigation of mutational status has to be obligatory in all patients for whom treatment correction is considered. Presence of ACA should also be taken into account in patients requiring administration of the second line TKI since they can adversely influence expected treatment response as well.
References
Andreyeva SV, Drozdova VD. [Guidelines for ana¬lysis of chromosome preparations in hematologic neoplasms]. Kyiv, 2007;44. Ukrainian. 2. Misiurin AV, Aksenova EV, Krutov AA, et al. [Mo¬lecular diagnostics of chronic myeloid leukemia]. Gematologia i transfuziologia. 2007;2:35-40. Russian. 3. Turkina AG, Khoroshko ND, Zaritskiy AY, et al. [Achievements in treatment of CML. Therapeutic prob-lems and ways of their solution, 2009 – 2012]. Vestnik ge¬matologii, 2009;V(2):44-45. Russian. 4. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018-29. 5. Khorrashad JS, Kelley TV, Szankasi P, et al. BCR-ABL1 compaund mutations in tyrosine kinase in-hibitor resistant CML: frequency and clonal relationship. Blood. 2013;121(3):489-98. 6. Soverini S, Hochhaus A, Nicolini FE, et al.BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European Leukemia Net. Blood. 2011;118(5):1208-215. 7. Baccarani M, Deininger MW, Rosti G, et al. European Leukemia Net recommendations for the mana-gement of cnronic myeloid leukemia: 1013. Blood. 2013;122(6):872-84. 8. Goldman JM. How I treat chronic myeloid leu-kemia in the imatinib era. Blood. 2007;110:2828-37. 9. O’Hare T, Walters DK, Stoffregen EP, et al. In vit-ro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-05. 10. Мilojkovic D, Apperley J. Mechanisms of resis-tanяce to imatinib and second-generation tyrosine inhi¬bi-tors in chronic myeloid leukemia. Clin Cancer Res. 2009;15:7519-27. 11. Cortes JE, Kantarjian H, Shah NP, et al. Pona¬tinib in refractory Philadelphia chromosome-positive leukemias. N. Eng. J. Med. 2012;367(22):2075-88. 12. Parker WT, Lawrence RM, Ho M, et al. Sensitive detection of BCR-ABL1 mutations in patients with chro-nic myeloid leukemia after imatinib resistance is pre-dictive of outcome during subsequent therapy. J Clin On-col. 2011;29(32):4250-9. 13. Nicolini FE, Ibrahim AR, Soverini S, et al.The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98:1510-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medical Perspectives
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
